| Literature DB >> 31709300 |
Nenia Baerbock1, Anke Mittelstädt2, Joachim Jähne2.
Abstract
BACKGROUND: Papillary thyroid carcinoma (PTC) has a favorable prognosis following one-stage surgical therapy, whereas two-stage resections bear the risk of increased morbidity and possibly impaired prognosis. To further elucidate the value of surgical re-exploration in PTC, a retrospective study was performed.Entities:
Keywords: hypocalcemia; prognosis; recurrent laryngeal nerve paralysis; two-stage resections
Year: 2019 PMID: 31709300 PMCID: PMC6817731 DOI: 10.1515/iss-2018-0023
Source DB: PubMed Journal: Innov Surg Sci ISSN: 2364-7485
Figure 1:Preoperative diagnostic work-up (n=187).
Extent of resection in two-stage surgery for PTC (n=80).
| Extent of resection | Patients | |
|---|---|---|
| n | % | |
| Lymph node dissection compartment I | 45 | 56.3 |
| Completion thyroidectomy and lymph node dissection compartment I | 34 | 42.5 |
| Total thyroidectomy with lymph node dissection compartment Ib | 1 | 1.3 |
Figure 2:RNLP after one-stage (n=107) and two-stage (n=80) surgery.
Figure 3:Hypocalcemia after one-stage (n=107) and two-stage (n=80) surgery.
Pathological characteristics of PTC (n=187).
| PTC (n=187) | PTC>10 mm (n=146) | PTC≤10 mm (n=41) | ||||
|---|---|---|---|---|---|---|
| n | % | n | % | n | % | |
| Tumor stage | ||||||
| T1a | 16 | 8.6 | 16 | 39.0 | ||
| T1b | 36 | 19.3 | 36 | 24.7 | ||
| T2 | 28 | 15.0 | 28 | 19.2 | ||
| T3 | 101 | 54.0 | 76 | 52.1 | 25 | 61.0 |
| T4a | 6 | 3.2 | 6 | 4.1 | ||
| Focality | ||||||
| Unifocal | 148 | 79.1 | 123 | 84.2 | 25 | 61.0 |
| Multifocal (unilateral) | 12 | 6.4 | 5 | 3.4 | 7 | 17.1 |
| Multifocal (bilateral) | 27 | 14.4 | 18 | 12.3 | 9 | 22.0 |
| Lymph node metastases | ||||||
| N0 | 126 | 67.4 | 97 | 66.4 | 29 | 70.7 |
| N1 | 61 | 32.6 | 49 | 33.6 | 12 | 29.3 |
| Distant metastases | ||||||
| M0 | 184 | 98.4 | 143 | 97.9 | 41 | 100 |
| M1 | 3 | 1.6 | 3 | 2.1 | 0 | 0 |
| Stage | ||||||
| I | 94 | 50.3 | 76 | 52.1 | 18 | 43.9 |
| II | 9 | 4.8 | 9 | 6.2 | ||
| III | 76 | 40.6 | 53 | 36.3 | 23 | 56.1 |
| IVa | 5 | 2.7 | 5 | 3.4 | ||
| IVc | 3 | 1.6 | 3 | 2.1 | ||
Figure 4:Recurrence-free survival (n=186).
Figure 5:Disease-specific survival (n=187).